Gareth

Father + Husband
Combat Veteran * P.P.C.L.I.
Albertan
Hound Dog Enthusiast

[Arch Biopartners Inc @archbiopartners]

🚨 Canada’s life sciences sector continues to outperform

🔗https://t.co/B7su9rl62j

The Globe and Mail, citing BDC, reports Canadian life sciences VC funds generated 19.9% average 10-year internal returns through 2026, ahead of ICT (14.9%) and cleantech (10.1%).

🔬 https://t.co/HhXKl6yH4q

#BiotechNews #ArchBiopartners

[Gareth @Hayt899]

This was a game changer!

[Mr. Uppy @MisterUppy]

The Saudis just bought into SLV.

Yes, the Saudi Central Bank.

Silver demand is about to get a whole new buyer class.

This is not retail FOMO.
This is GAME CHANGING.

[Garrett Goggin, CFA & CMT @GarrettGoggin]

Insiders stepping up today at @AyaGoldSilver including CEO LaSalle.
https://t.co/iG8aUnItRT

[Chronic Disease Care @ICDC_Research]

Arch Biopartners Acquires Breakthrough CKD Platform—Pioneering a New Era in Kidney Therapeutics, Led by Dr. Justin Chun & Supported by Dr. Daniel Muruve.
#Biotech #CKD #Innovation

https://t.co/2jUWaWYXSA

@SnyderInstitute

[Arch Biopartners Inc @archbiopartners]

📈 Canadian investors are missing late-stage biotech opportunities, says Investment Executive (link below).

Arch Biopartners is supporting two Phase II trials to prevent AKI, a serious kidney condition with no approved therapies.

📊 https://t.co/n2T14MCicD

#AKI #KidneyCare #ArchBiopartners #InvestorFAQ #ArchScience

Full article at Investment Executive: https://t.co/Er4SBva05E

[Arch Biopartners Inc @archbiopartners]

🔍 A 2022 JASN consensus (https://t.co/7dr8CKw7gu) calls for smarter AKI trial design: focused subtypes like CS-AKI, stronger biomarkers, clearer endpoints.

Arch Biopartners is supporting two Phase II trials targeting CS-AKI and DI-AKI.

🔬 https://t.co/HhXKl6yH4q

#CSAKI #AKI #TrialRationale #ArchScience #ArchBiopartners

[Kevin W. @Brink_Thinker]

After being deployed in Kuwait for 7 months, she surprised her 3-year-old daughter and boyfriend. 🫶

[Arch Biopartners Inc @archbiopartners]

🚀 1st Canadian patient dosing complete at @UCalgaryMed 🏥 in the Arch Biopartners Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury. Follow for news about @UHN and @UnityHealthTO sites to come. https://t.co/K9Zqp6M6Bx #AKI #ClinicalTrials

[Arch Biopartners Inc @archbiopartners]

2024 Conferences
👉 Arch Biopartners is attending @ASNKidney Kidney Week 2024, San Diego, October 23-27.
In November, the company will be presenting at Bio-Europe 2024, 🤝 Europe’s premier partnering event, Stockholm, November 4-13. #BioEurope - https://t.co/phep0L6FhB

[Arch Biopartners Inc @archbiopartners]

Arch Biopartners is proud to be participating in @tsx_tsxv Life Sciences Investor Day. CEO, Richard Muruve will discuss the company's ongoing work to advance therapeutics to prevent organ inflammation. Learn about our science, research and clinical trials https://t.co/9o8CBRY38W

[Gareth @Hayt899]

🧵 16. $Arch.v $Achff

"The addition of UHN "Toronto General Hospital" as the second Canadian hospital site increases the number of trial sites to eight, with six active clinical sites in Turkey"

https://t.co/yBaHgSZOsR

[Gareth @Hayt899]

🧵 1. $Arch.v $Achff

@BMJ_Open published scientific rationale for @archbiopartners to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications, including cardiac surgery-associated AKI. Find the development of the LSALT Program below:

[Gareth @Hayt899]

🧵 15. $Arch.v $Achff

"strong experimental and clinical evidence has indicated that CXCL10 is involved in the development of renal diseases through the chemoattraction of inflammatory cells and facilitation of cell growth and angiostatic effects."

https://t.co/tJkzXo6bjT